MSLN and ovarian carcinoma: In phase I study for mesothelin targeted therapies, 2.4 mg/kg of mesothelin-targeting antibody-based drug administered three times a week showed safety and partial responses in 3 of 10 (30%) patients with platinum-resistant ovarian cancer [36].